Suhrad G Banugaria from Whippany, NJ, age 41

Method Of Treating Patients Undergoing Protein Replacement Therapy, Gene Replacement Therapy, Or Other Therapeutic Modalities
view source
US Patent:

20130052189, Feb 28, 2013
Filed:

May 6, 2011
Appl. No.:

13/696388
Inventors:

Priya S. Kishnani - Durham NC, US
Suhrad G. Banugaria - Durham NC, US
Dwight D. Koeberl - Durham NC, US
Sean N. Prater - Durham NC, US
International Classification:

A61K 31/69
A61P 43/00
A61K 39/395
US Classification:

4241301, 514 64
Abstract:

The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.

Method Of Reducing Titers Of Antibodies Specific For A Therapeutic Agent
view source
US Patent:

20180117111, May 3, 2018
Filed:

Oct 27, 2017
Appl. No.:

15/796137
Inventors:

- Durham NC, US
Suhrad G. Banugaria - Durham NC, US
Dwight D. Koeberl - Durham NC, US
Sean N. Prater - Durham NC, US
International Classification:

A61K 38/05
A61K 38/17
C07K 16/28
A61K 31/519
A61K 39/395
A61K 39/00
Abstract:

The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.

Method Of Reducing Titers Of Antibodies Specific For A Therapeutic Agent
view source
US Patent:

20170165316, Jun 15, 2017
Filed:

Feb 21, 2017
Appl. No.:

15/438375
Inventors:

- Durham NC, US
Suhrad G. Banugaria - Durham NC, US
Dwight D. Koeberl - Durham NC, US
Sean N. Prater - Durham NC, US
International Classification:

A61K 38/05
A61K 39/395
C07K 16/28
A61K 31/519
A61K 38/17
Abstract:

The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.

Method Of Reducing Titers Of Antibodies Specific For A Therapeutic Agent
view source
US Patent:

20150037329, Feb 5, 2015
Filed:

Aug 7, 2014
Appl. No.:

14/454137
Inventors:

- Durham NC, US
Suhrad G. Banugaria - Durham NC, US
Dwight D. Koeberl - Durham NC, US
Sean N. Prater - Durham NC, US
Assignee:

DUKE UNIVERSITY - Durham NC
International Classification:

A61K 31/69
C07K 16/28
A61K 38/17
A61K 39/395
A61K 31/519
US Classification:

4241331, 514 64
Abstract:

The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.

Suhrad G Banugaria